ACG, integrated supplier to the pharmaceutical industry, has signed an MoU with the Government of Maharashtra to set up what it claims will be Asia’s largest manufacturing plant and R&D centre at Aurangabad in Maharashtra, to produce 40 billion capsules a year. The plant will serve both Indian and international pharmaceutical and nutraceutical companies.
Karan Singh, MD, ACG, said: “Our vision to be a future-ready solutions provider to the pharma industry anywhere in the world and our proposed investment of approximately USD$ 100 million (over INR 600 crores) in this state-of-the-art plant, is an integral part of ACG’s mission to double our capsule manufacturing capacity to 240 billion capsules a year.” He adds, “This plant will play a key role in further cementing India’s position as the global hub of capsule manufacturing and will add to improved access to high quality, safe and affordable medicines and nutraceuticals globally.”
Nitin Desai, Senior VP, ACG, said: “We have a long history of operating in Maharashtra and are privileged to sign this MOU with Government of Maharashtra for this mega project which when ready by 2023 will create around 1000 direct and indirect jobs in the region.”
The plant will employ key design principles from the Leadership in Energy and Environmental Design (LEED) scheme, the company says, and will be powered significantly by green renewable energy. It will also employ automation and industry 4.0 technologies aimed to minimise resource intensity and ensure products meet good manufacturing practices (GMP).
